Bioject Medical Technologies
This article was originally published in The Gray Sheet
Bioject Medical Technologies: Shareholders adopt a proposal to exchange a $12 mil. note held by Bioject joint venture partner Elan for about 832,000 shares of newly authorized Series A and Series B convertible preferred stock of Bioject. Stockholders also authorized the issuance of up to $4 mil. of Series C convertible preferred stock to Elan to fund further development of a continuous glucose level monitoring system for diabetics. The move finalizes financing arrangements related to a joint venture between Bioject and Elan forged in October 1997 for development of the device ("The Gray Sheet" Oct. 20, p. 17)...
You may also be interested in...
ResMed plans to double or even triple production of intensive ventilators and sleep apnea machines this year amid rising demand by hospitals to use CPAP and BPAP machines to treat COVID-19 patients during the ventilator shortage.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.